Skip to content

Advertisement

Thyroid Research

Research
Open Access

Hashimoto thyroiditis is more frequent than expected when diagnosed by cytology which uncovers a pre-clinical state

  • Anca Staii1,
  • Sarah Mirocha1,
  • Kristina Todorova-Koteva1,
  • Simone Glinberg1 and
  • Juan C Jaume1Email author
Thyroid Research20103:11

https://doi.org/10.1186/1756-6614-3-11

©  Staii et al; licensee BioMed Central Ltd. 2010

Received: 15 July 2010

Accepted: 20 December 2010

Published: 20 December 2010

Abstract

Background

Our Thyroid-Multidisciplinary Clinic is a large referral site for thyroid diseases. Thyroid biopsies are mainly performed for thyroid cancer screening. Yet, Hashimoto thyroiditis (HT) is being too frequently diagnosed. The prevalence of HT is reported as 0.3-1.2% or twice the prevalence of type 1 diabetes. However, the prevalence of HT confirmed by cytology is still uncertain. To evaluate different aspects of thyroid physiopathology including prevalence of Hashimoto's, a database of clinical features, ultrasound images and cytology results of patients referred for FNA of thyroid nodules was prospectively developed.

Methods

We retrospectively studied 811 consecutive patients for whom ultrasound guided thyroid FNA biopsies were performed at our clinic over 2.5 year period (Mar/2006-Sep/2008).

Results

The analysis of our database revealed that from 761 patients, 102 (13.4%) had HT, from whom 56 (7.4%) were euthyroid or had sub-clinical (non-hypothyroid) disease, and 46 (6%) were clinically hypothyroid.

Conclusions

This is the first study to show such a high prevalence of HT diagnosed by ultrasound-guided FNA. More strikingly, the prevalence of euthyroid HT, appears to be >5% similar to that of type 2 diabetes. Based on our results, there might be a need to follow up on cytological Hashimoto's to monitor for thyroid failure, especially in high risk states, like pregnancy. The potential risk for thyroid cancer in patients with biopsy-proven inflammation of thyroid epithelium remains to be established prospectively. However, it may explain the increased risk for thyroid cancer observed in patients with elevated but within normal TSH.

Keywords

Thyroid HormoneThyroid CancerFine Needle AspirationThyroid NoduleDifferentiate Thyroid Cancer

Background

Hashimoto thyroiditis is the most common cause of hypothyroidism in the United States [1]. With a 5-10 time preference over men, the reported prevalence in white women is in the 1-2% range [2].

Etiology and pathogenesis of Hashimoto thyroiditis are still elusive. Moreover, little is known about progression of euthyroid to hypothyroid Hashimoto's. At least in children, disease progression from euthyroid to hypothyroid Hashimoto thyroiditis has been suggested [3]. Also, available evidence relating the progression of sub-clinical to overt hypothyroidism in adults has been rated as good [4]. Hence, it is conceivable that a euthyroid stage of Hashimoto thyroiditis exists and that progression to a full-blown disease stage is a matter of time.

Since there is growing evidence that unrecognized hypothyroidism is deleterious, early diagnosis of Hashimoto thyroiditis would be advantageous in predicting thyroid failure. Specifically, it is well known that maternal thyroid status assessment and treatment improves fetal outcomes and neuropsychological developmental of the newborn [5].

The University of Wisconsin Thyroid Multidisciplinary Clinic is a large referral site for thyroid diseases in the Midwest. A continuously increasing number of thyroid biopsies are being performed every year for cancer screening. Yet, Hashimoto thyroiditis is being too frequently diagnosed. The prevalence of Hashimoto thyroiditis is reported to be approximately twice that of type 1 diabetes. However, the prevalence of Hashimoto thyroiditis confirmed by cytology has never been documented in a large cohort of patients with ultrasound detectable nodules. To evaluate different aspects of thyroid physiopathology, a database of clinical features, ultrasound images and cytology results of patients referred for fine needle aspiration of thyroid nodules was prospectively developed. In this paper we probed our database for the frequency and characteristic of patients diagnosed with Hashimoto thyroiditis while being referred for thyroid cancer screening.

Methods

Thyroid Database

From March 2006 until September 2008, 811 patients underwent ultrasound guided fine needle aspiration (FNA) biopsy of thyroid nodules for screening of thyroid cancer. After excluding 50 patients who were either no-show or their specimens were non-diagnostic, we retrospectively studied 761 consecutive patients for which ultrasound guided thyroid FNA biopsies were performed at our clinic (Figure 1). All FNA samples were reviewed by cytopathologists at our institution.
Figure 1

Patients' allocation diagram.

The Hashimoto thyroiditis cohort consisted of 102 (13.4%) patients (659 out of 761 did not have cytological Hashimoto's diagnosis) for which 46 (6%) were identified as having clinical disease (i.e. diagnosed hypothyroid on thyroid hormone replacement and with cytological Hashimoto's diagnosis), 9 (1.2%) as having sub-clinical hypothyroidism (as defined by normal thyroid hormones with above normal [usually less than 10 ng/dl] TSH and with cytological Hashimoto's diagnosis) and 47 (6.2%) as having euthyroid autoimmunity (as defined by normal thyroid hormones with normal [0.45-4.12 ng/dl] TSH but with cytological Hashimoto's diagnosis). For all patients, data were collected for: age, gender, nodule size and number of nodules, levels of TSH/FT4, presence of TPO (thyroid peroxidase) autoantibodies, family history of Hashimoto's, goiter, and autoimmune diseases. The collection of patient's data and subsequent analysis was approved by University of Wisconsin Human Subjects Institutional Review Board.

Statistical Analysis

Data analysis was conducted using Excel X2 and Fisher's exact test and Student t-test were used when appropriate. Statistical significance was defined as P < 0.05.

Results

Patients Characteristics

Patients were referred to the University of Wisconsin Thyroid Multidisciplinary Clinic usually for evaluation of an already diagnosed thyroid problem. Thyroid nodules ≥ 1 cm were biopsied under ultrasound guidance mainly to screen for thyroid cancer. On-site cytopathology was available for every single case. Endocrine surgery referral was also available as needed during the same encounter. A database was started with the inauguration of the clinic and recruitment is ongoing. Of the first 811 patients' data analyzed, an unexpected large number of patients with positive Hashimoto thyroiditis cytology were identified. The analysis of our database revealed that from 761 patients, 102 (13.4%) had cytology proven Hashimoto thyroiditis. Patients' characteristics of this cohort are shown on table 1. Hashimoto thyroiditis cohort consisted of 94 female and 8 male with mean (± SD) age of 47 ± 14 years. Out of these 102 patients with cytology-proven Hashimoto thyroiditis, 47 (6.2%) were euthyroid, 9 (1.2%) had sub-clinical hypothyroidism, and 46 (6%) had clinical hypothyroidism and were on thyroid hormone replacement (Table 1 and Figure 2). The number of nodules was 1.43 ± 0.54 average for the clinically hypothyroid subgroup, 1.77 ± 0.66 average for the sub-clinical subgroup (p < 0.05 when compared to clinically hypothyroid subgroup) and 1.58 ± 0.71 for the euthyroid subgroup. The size of the nodules was 1.42 ± 0.42; and 1.55 ± 0.81; for the clinical and sub-clinical subgroups respectively and 1.69 ± 0.74 (p < 0.05, also Table 1) for the euthyroid subgroup. Although differences between nodules sizes of clinically hypothyroid versus sub-clinical subgroups appear significant, the result of this comparison is skewed by the low number of patients in the sub-clinical subgroup as well as the wider range. Larger size of euthyroid subgroup nodules was however statistically significant when compared to clinically hypothyroid subgroup nodules both subgroups with similar number of nodules. Another significance difference was also observed in the comparison of TSH values between euthyroid and clinically hypothyroid subgroups as expected. The clinically hypothyroid subgroup had an average TSH of 8 ± 2.61 ng/dl while the euthyroid subgroup had a lower TSH of 2.18 ± 1.14 ng/dl. The sub-clinical subgroup had average TSH value of 6.73 ± 1.26 ng/dl. All nodules were reported as benign. Of note, although patients with clinical hypothyroidism were all taking thyroid hormone, none in the sub-clinical or the euthyroid subgroups were on thyroid hormone replacement. FT4 (free T4) in the clinically hypothyroid subgroup was found to be 1 ± 0.36; 0.96 ± 0.11 in the sub-clinical and 0.92 ± 0.11 in the euthyroid subgroup. FT4 however was not recorded in 52% of the clinically hypothyroid subgroup and in 56/57% of the sub-clinical/euthyroid subgroups respectively. Not recorded also, was the presence or absence of TPO autoantibodies in 30 of 46 patients with clinical hypothyroidism, 6 of 9 patients with sub-clinical and 34 of 47 with euthyroid Hashimoto's. However out of the recorded TPO autoantibodies, 13 of 16 (81.3%) were positive in the clinically hypothyroid subgroup while 8 of 16 (50%) were positive in the sub-clinical/euthyroid subgroups (also in Table 1). There were no significant differences among euthyroid, sub-clinical and clinically hypothyroid Hashimoto thyroiditis subgroups in terms of age, gender, family history of Hashimoto's, goiter, and/or autoimmune diseases (also in Table 1).
Figure 2

Prevalence comparison. Chart comparison is provided between this study and NHANES III (9). The total population of NHANES III study is used as a reference for the comparison of clinical and subclinical disease in both studies.

Table 1

Patients Characteristics - Hashimoto Thyroiditis Patients*

 

Clinically hypothyroid

Sub-clinically hypothyroid

1st P-value**

Euthyroid

2nd P-value**

FNA patients

46

9

 

47

 

Age (years)

47 ± 12

50 ± 17

0.53

46 ± 15

0.72

Gender

     

   Male

2 (4%)

2 (22%)

0.15

4 (9%)

0.68

   Female

44 (96%)

7 (78%)

0.79

43 (92%)

1

Nodule

     

   # of nodules

1.43 ± 0.54

1.77 ± 0.66

<0.05

1.58 ± 0.71

0.26

   Size

1.42 ± 0.42

1.55 ± 0.81

0.48

1.69 ± 0.74

<0.05

TSH(0.45-4.12 ng/dl)

8 ± 2.61

6.73 ± 1.26

0.16

2.18 ± 1.14

<0.05

FT4

1 ± 0.36

0.96 ± 0.11

0.74

0.92 ± 0.11

0.15

   Not Recorded

24 (52%)

5 (56%)

 

27 (57%)

 

   Recorded

22 (48%)

4 (44%)

 

20 (43%)

 

TPO antibodies

     

   Not Recorded

30

6

 

34

 

   Positive

13

1

0.62

7

0.56

   Negative

3

2

0.27

6

0.45

FHx of Hashimoto's/goiter/autoimmunity

18 (39%)

4 (44%)

1

10 (21%)

0.19

* Values reported as mean ± SD.

** Fisher exact test and Student t-test. 1st P-value is between Clinically and Sub-clinically hypothyroid. 2nd P-value is between Clinically hypothyroid and Euthyroid. Statistically significant values are shown in italics.

Hashimoto thyroiditis more common than expected

Although the prevalence of Hashimoto thyroiditis diagnosed by ultrasound guided FNA cytology has not been established, the prevalence found in our cohort was unexpectedly high in comparison with that reported for Hashimoto's hypothyroidism and subclinical disease combined (Figure 2). The reasons for these differences in prevalence estimates are not obvious. Hence we considered potential factors that might have biased the results. Among them, the clinical indications for the biopsies and the cytological criteria for Hashimoto thyroiditis diagnosis were reviewed for all cases. Clinical indications for biopsies of nodules were based on the American Thyroid Association guidelines for size criteria (see nodule sizes in Table 1) which were determined by ultrasound before and confirmed during the biopsy (Figure 3A as example). Standard cytological characteristics for diagnosis were also followed by our cytologists as described by Kini [6]. The cytological diagnosis of Hashimoto's thyroiditis relied on the presence of both an inflammatory infiltrate accompanied by thyroid follicular cells. Mixed population of lymphocytes, sometimes represented in the form of crushed lymphocytes and lymphoglandular bodies (cytoplasmic debris) together with the presence of Hurthle cells were described in all cytology reports (Figure 3B as example). All of these characteristics were considered in the diagnosis of each and every patient in our cohort. Lastly, our referral population is broad but representative of an area considered iodine sufficient.
Figure 3

A. Ultrasound image of euthyroid Hashimoto thyroiditis. A representative ultrasound is shown of an asymptomatic, euthyroid patient's thyroid nodule cytologically diagnosed Hashimoto thyroiditis. Note the minimal color flow Doppler identified within the nodule. B. Cytopathology. Cytological characteristics of a thyroid nodule with typical diagnostic features of Hashimoto's thyroiditis (i.e. lymphocytic infiltrate, Hurthle cells, lymphoglandular bodies and crushed lymphocytes).

Discussion

This is the first study to show such a high prevalence of Hashimoto thyroiditis diagnosed by ultrasound-guided FNA cytology on a somewhat large cohort of patients. Based on our study, the prevalence of cytology-proven Hashimoto thyroiditis appears to be >10% in patients with thyroid nodules. Given that the prevalence of thyroid nodules on ultrasonography or autopsy data is as high as 50% [7], such a high prevalence of Hashimoto thyroiditis diagnosed by cytology is noteworthy. More strikingly, the prevalence of euthyroid, non-previously diagnosed, cytology-proven Hashimoto thyroiditis (euthyroid autoimmunity), appears to be >5% in our study (Figure 1 and 2). This condition has not been previously defined. For comparison, its prevalence is similar to that of type 2 diabetes which is considered to be a health care crisis.

Weetman [2] reported clinical Hashimoto thyroiditis prevalence rate at 1 in 182 or 0.55% in the US. In the UK, Tunbridge et al [8] reported an overall Hashimoto thyroiditis prevalence of 0.8%. However, based on our study, the cytology of Hashimoto thyroiditis seems to be much more prevalent, at 13.4%. This difference may be partially explained by the fact that for diagnosing clinical Hashimoto thyroiditis, abnormally elevated TSH, low thyroid hormones [2, 8] and the confirmatory presence of thyroid autoantibodies are usually accounted for. We hypothesized then, that cytological diagnosis of Hashimoto's may precede clinical diagnosis. Interestingly however, in most organ specific autoimmune diseases, humoral immunity heralds tissue infiltrative damage. Hence, we expected the diagnosis of Hashimoto's by cytology to be less but not more common than the antibody diagnosis especially on early stages of the disease (Figure 2).

In an attempt at differentiating better the apparent stages of Hashimoto thyroiditis, we divided our cytology-proven Hashimoto's cohort into three subgroups: clinically hypothyroid, sub-clinical and euthyroid. For these distinctions, we used the clinical definition of hypothyroid Hashimoto thyroiditis as that occurring in patients usually with TSH greater than 10 ng/dl at diagnosis, with low free thyroid hormones and on thyroid hormone replacement. Based on NHANES III study [9] normative data for TSH distribution (reference population of 13,344, 95% of TSH between 0.45-4.12 ng/dl), abnormally high TSH (but usually less than 10 ng/dl) with normal thyroid hormones was used to define sub-clinical hypothyroidism. Patients with those characteristics were assigned to the sub-clinical subgroup in our study. A third subgroup classified as euthyroid included patients with normal thyroid hormones and normal TSH.

Aside from the unexpected observation of the high prevalence of Hashimoto thyroiditis by cytology, especially in euthyroid patients, the lack of cytological correlation with TPO autoantibody positivity is noteworthy. As mentioned before, the hallmark in the diagnosis of Hashimoto thyroiditis is the presence of TPO autoantibodies [10]. Yet, only about half of the patients tested for anti-TPO in the euthyroid subgroup were positive. On the other hand and although non-statistically significant because of the small number reported, the clinically hypothyroid subgroup had most (13 out of 16 tested) patients positive for anti-TPO. Similarly, Poropatich et al., [11] found that anti-TPO and/or antithyroglobulin antibody titers were present in only 50% of the patients with euthyroid, cytology-proven Hashimoto thyroiditis, a finding never reproduced by these or other authors in the literature.

Given the wide range of normal values for TSH (1 fold) and the variability on the presence of TPO autoantibodies, it is conceivable that early Hashimoto's autoimmune process might be clinically missed. These issues, together with the awareness that sub-clinical and clinical hypothyroidism associates with cardiovascular and neuropsychiatric morbidities, make finding high prevalence of Hashimoto thyroiditis on cytology, especially in euthyroid patients clinically significant [12–14].

An important aspect of our findings is the fact that most of the patients in our cohort are pre-menopausal females. Past and more recent studies found that the risk of poor obstetrical outcome is increased with relative thyroxine deficiency [15–18]. Benhadi et al. recently showed that the risk of miscarriage, fetal and neonatal death is increased with higher TSH levels. Moreover, the risk of fetal loss occurred even when maternal free thyroxine levels were normal [16]. Based on our results of high prevalence of cytology-proven Hashimoto thyroiditis and especially high prevalence of euthyroid disease in pre-menopausal women, there might be need of at least follow up of thyroid function on cytologically-proven Hashimoto's in pre-conception through delivery stages.

Positive Hashimoto's cytology clearly represents a state in which inflammation of thyroid epithelium may lead to tissue remodeling. Hence the possibility of acquiring mutations while cells are dividing might be greater. Some studies have suggested that inflammation of thyrocytes could be linked to thyroid cancer [19–21]. For example, Larson et al. showed that phosphatidylinositol 3-kinase phosphorilates Akt, which in turn suppresses pro-apoptotic signals and promotes tumorigenesis, was increased in both Hashimoto thyroiditis and well differentiated thyroid cancer [19]. Furthermore, Borrello et al., showed that RET/PTC oncogene, when exogenously expressed in normal thyrocytes, induces expression of a large set of genes involved in inflammation and tumor invasion (cytokines, matrix-degrading enzymes and adhesion molecules) [20]. There seem to be however, controversial opinions regarding the association of Hashimoto thyroiditis and thyroid cancer. Some studies find Hashimoto thyroiditis as associated with thyroid cancer [22, 23] as examples, while others do not report an association [24, 25] as examples. Since higher TSH level in patients with thyroid nodules has been found to be associated with risk of differentiated thyroid cancer [26, 27], we hypothesized that active remodeling of thyroid epithelium in cytological Hashimoto's may explain in part the increased risk for differentiated thyroid cancer observed in patients with elevated but within normal TSH [26, 27].

Conclusions

We report here that the pathogenesis of Hashimoto thyroiditis is present in an unexpectedly large number of individuals. Moreover, we found that many of these individuals carry a non-clinically manifested process. Biopsy proven Hashimoto thyroiditis in asymptomatic, clinically disease-free patients is a condition still undefined. There are no guidelines as to how to follow these patients. What is their risk of progressing to full-blown Hashimoto's? How would pregnancy affect their thyroid function? Are they at further risk of developing thyroid cancer since their TSH usually runs in the normal but higher quartile? Recognition of this entity emerges as necessary at least in patients at risk for hypothyroid complications (i.e. pregnancy). If the cytology of Hashimoto thyroiditis represents a chronic active inflammatory state, TSH elevations within normal limits may represent a manifestation of a common underlying process.

List of abbreviations used

HT: 

Hashimoto thyroiditis

FHx: 

Family history

FT4: 

Free T4

FNA: 

Fine needle aspiration

TPO: 

Thyroid peroxidase.

Declarations

Aknowledgements

We would like to thank Drs. Haymart, Heras-Herzig, Gogineni, Bradley, and Poehls for their active participation in the ongoing University of Wisconsin Thyroid Database Study and Dr. Ernest L. Mazzaferri for critical review of this paper. This work was funded in part by NIH and VA grants (JCJ) and presented in part at the 2009 Endocrine Society Annual Meeting, USA.

Authors’ Affiliations

(1)
Endocrinology, Diabetes and Metabolism, Department of Medicine, School of Medicine and Veterans Affairs Medical Center, University of Wisconsin-Madison, Madison, USA

References

  1. Jaume JC: Endocrine autoimmunity. In Greenspan's Basic & Clinical Endocrinology. Edited by: Gardner DG, Shoback DM. New York: McGraw-Hill Medical; 2007:59–79.Google Scholar
  2. Weetman AP: Thyroid disease. In The Autoimmune Disease. Edited by: Rose NR, Mackay IR. Elsevier; 2006:467–482. full_textView ArticleGoogle Scholar
  3. Radetti G, Gottardi E, Bona G, Corrias A, Salardi S, Loche S: Study Group for Thyroid Diseases of the Italian Society for Pediatric Endocrinology and Diabetes (SIEDP/ISPED). The natural history of euthyroid Hashimoto's thyroiditis in children. J Pediatr 2006, 149: 827–832. 10.1016/j.jpeds.2006.08.045PubMedView ArticleGoogle Scholar
  4. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ: Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004, 291: 228–238. 10.1001/jama.291.2.228PubMedView ArticleGoogle Scholar
  5. Brent GA: Diagnosing thyroid dysfunction in pregnant women: is case finding enough? J Clin Endocrinol Metab 2007, 92: 39–41. 10.1210/jc.2006-2461PubMedView ArticleGoogle Scholar
  6. Kini SR: Thyroiditis. In Thyroid Cytopathology. Edited by: Kini SR. Philadelphia Lippincott, Williams and Wilkins; 2008:288–323.Google Scholar
  7. Mazzaferri EL: Managing small thyroid cancers. JAMA 2006, 295: 2179–2182. 10.1001/jama.295.18.2179PubMedView ArticleGoogle Scholar
  8. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, Evans JG, Young E, Bird T, Smith PA: The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977, 7: 481–493. 10.1111/j.1365-2265.1977.tb01340.xView ArticleGoogle Scholar
  9. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE: Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002, 87: 489–499. 10.1210/jc.87.2.489PubMedView ArticleGoogle Scholar
  10. Jaume JC, Costante G, Portolano S, McLachlan SM, Rapoport B: Recombinant thyroid peroxidase-specific autoantibodies. I. How diverse is the pool of heavy and light chains in immunoglobulin gene libraries constructed from thyroid tissue-infiltrating plasma cells. Endocrinology 1994, 135: 16–24. 10.1210/en.135.1.16PubMedGoogle Scholar
  11. Poropatich C, Marcus D, Oertel YC: Hashimoto's thyroiditis: fine-needle aspirations of 50 asymptomatic cases. Diagn Cytopathol 1994, 11: 141–145. 10.1002/dc.2840110207PubMedView ArticleGoogle Scholar
  12. Surks MI, Ocampo E: Subclinical thyroid disease. Am J Med 1986, 100: 217–223. 10.1016/S0002-9343(97)89462-4View ArticleGoogle Scholar
  13. Helfand M, Redfern CC: Screening for thyroid disease: an update. Ann Intern Med 1998, 129: 144–158.PubMedView ArticleGoogle Scholar
  14. Cooper DS: Subclinical thyroid disease: a clinician's perspective. Ann Intern Med 1998, 129: 135–137.PubMedView ArticleGoogle Scholar
  15. Hak AE, Pols HAP, Visser TJ, Drexhage HA, Hofman A, Witteman JCM: Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med 2000, 132: 270–278.PubMedView ArticleGoogle Scholar
  16. Benhadi N, Wiersinga WM, Reitsma JB, Vrijkotte TG, Bonsel GJ: Higher maternal TSH levels in pregnancy are associated with increased risk for miscarriage, fetal or neonatal death. Eur J Endocrinol 2009, 160: 985–991. 10.1530/EJE-08-0953PubMedView ArticleGoogle Scholar
  17. Klein RZ, Haddow JE, Faix JD, Brown RS, Hermos RJ, Pulkkinen A, Mitchell ML: Prevalence of thyroid deficiency in pregnant women. Clin Endocrinol (Oxf) 1991, 35: 41–46. 10.1111/j.1365-2265.1991.tb03494.xView ArticleGoogle Scholar
  18. Allan WC, Haddow JE, Palomaki GE, Williams JR, Mitchell ML, Hermos RJ, Faix JD, Klein RZ: Maternal thyroid deficiency and pregnancy complications: implications for population screening. J Med Screen 2000, 7: 127–130. 10.1136/jms.7.3.127PubMedView ArticleGoogle Scholar
  19. Larson SD, Jackson l, Riall TS, Uchida T, Thomas RP, Qiu S, Evers BM: Increased of Well-Differentiated Thyroid Cancer Associated with Hashimoto Thyroiditis and the Role of the PI3k/Akt pathway. J Am Coll Surg 2007, 204: 764–773. 10.1016/j.jamcollsurg.2006.12.037PubMed CentralPubMedView ArticleGoogle Scholar
  20. Borrello MG, Alberti L, Fischer A, Degl'innocenti D, Ferrario C, Gariboldi M, Marchesi F, Allavena P, Greco A, Collini P, Pilotti S, Cassinelli G, Bressan P, Fugazzola L, Mantovani A, Pierotti MA: Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci USA 2005, 102: 14825–14830. 10.1073/pnas.0503039102PubMed CentralPubMedView ArticleGoogle Scholar
  21. Rhoden KJ, Unger K, Salvatore G, Yilmaz Y, Vovk V, Chiappetta G, Qumsiyeh MB, Rothstein JL, Fusco A, Santoro M, Zitzelsberger H, Tallini G: RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab 2006, 91: 2414–2423. 10.1210/jc.2006-0240PubMedView ArticleGoogle Scholar
  22. Dailey ME, Lindsay S, Skahen R: Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg 1955, 70: 291–297.PubMedView ArticleGoogle Scholar
  23. Repplinger D, Bargren A, Zhang YW, Adler JT, Haymart M, Chen H: Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? J Surg Res 2008, 150: 49–52. 10.1016/j.jss.2007.09.020PubMed CentralPubMedView ArticleGoogle Scholar
  24. Holm LE, Blomgren H, Löwhagen T: Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med 1985, 312: 601–604. 10.1056/NEJM198503073121001PubMedView ArticleGoogle Scholar
  25. Rago T, Di Coscio G, Ugolini C, Scutari M, Basolo F, Latrofa F, Romani R, Berti P, Grasso L, Braverman LE, Pinchera A, Vitti P: Clinical features of thyroid autoimmunity are associated with thyroiditis on histology and are not predictive of malignancy in 570 patients with indeterminate nodules on cytology who had a thyroidectomy. Clin Endocrinol (Oxf) 2007, 67: 363–369. 10.1111/j.1365-2265.2007.02892.xView ArticleGoogle Scholar
  26. Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, Chen H: Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 2008, 93: 809–814. 10.1210/jc.2007-2215PubMed CentralPubMedView ArticleGoogle Scholar
  27. Haymart MR, Glinberg SL, Liu J, Sippel RS, Jaume JC, Chen H: Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clin Endocrinol (Oxf) 2009, 71: 434–439. 10.1111/j.1365-2265.2008.03489.xView ArticleGoogle Scholar

Copyright

© Staii et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement

Thyroid Research

ISSN: 1756-6614